原发性肝癌来源的肿瘤浸润淋巴细胞的生物学特性分析  

Biological Characteristic Analysis of TIL From Patients with Hepatocellular Carcinoma

作　　者：陈敏[1] 叶胜龙[1] 吴志全[1] 樊嘉[1] 邱双健[1] 孙瑞霞[1] 薛琼[1] 郑宁[1] 赵燕[1] 汤钊猷[1] 

机构地区：[1]上海医科大学肝癌研究所,200032

出　　处：《中国临床医学》1999年第1期8-11,共4页Chinese Journal of Clinical Medicine

基　　金：上海市医学领先学科及美国中华医学基金会!(93583)资助

摘　　要：目的：通过对肝癌来源的肿瘤浸润淋巴细胞（TIL）生物学特性的分析，了解肝癌与机体之间的相关性，为进一步增强TIL的抗肿瘤作用提供一定的实验依据。材料与方法：取我所26例肝癌手术切除标本，分离培养淋巴细胞，用流式细胞仪对细胞表型进行测定，并以裸鼠为实验动物，观察TIL的抗肿瘤作用。结果：经rIL－2体外扩增后，大多为成熟的CD3+T细胞，百分比为86.31％±13.08％，CD4+／CDS+的比率小于1。TIL中CDlla阳性细胞比例为7454％±16,93％，而LAK细胞的CD11a阳性细胞比例为26.72％±15.73％，两者差异有显著性。在体内外实验中均观察到TIL的抗肿瘤作用。结论：1）肝癌TIL有肿瘤导向的相对特异性，细胞毒作用参与TIL杀伤肿瘤细胞；2）TIL易与靶细胞密切接触为TIL杀伤活性强的因素之一。Objective: We analysed biological characteristics of TIL from HCC in this study, aiming to clarify the relationshipbetween the characteristics of TIL and prognosis of HCC. Materials and Methods 26 specimens were taken from Sept. 1996 toFeb. 1998 with pathologically proven as HCC, accompanied by liver cirrhosis. TIL were obtained according to Whiteside rou-tine methods. After 20 days incubation period, TIL were harvested for phenotype analysis. Results: Considering LFA - 1/l-CAM - 1 interaction which is important in T - lymphocyte activation, proliferation and signal transduction, we took LFA - 1(CD11 a/CD 18) as a parameter in this study to study if there is difference between TIL and LAK. TIL were used in antitu-mor efficacy expermnent in vivo and in vitro. The phenotype analysis showed that most TIL were CD3 positive T - lympho-cytes, (86. 31 % ±13. 08 % ), with CD 4 + /CD 8+ ratio less than 1, which was different from PBL. The CD11 a positive rate ofTIL was 74. 54 % ±16. 93 %, while that of LAK was 26. 72 % ±16. 93 % (p<0. 01 ). Obvious antitumor reactivity by TILwas found in vivo and in vitro. Conclusion: 1 ) TIL as a biological therapy is feasible in liver cancer treatment, 2) Differentmechanisms between LAK and TIL are involved in antitumor reactivity, 3) TIL provides a base for further research on HCC.

关 键 词：肿瘤浸润 淋巴细胞 肝癌 生物学特性 

分 类 号：R735.702[医药卫生—肿瘤]